Jean Pfau and Tracy McNew highlight the ongoing health risks and the need for updated evaluations of the remediation efforts at The Libby Asbestos Superfund Site ...

Robert Melvin, Northeast Region Director, R Street Institute In SUPPORT of Senate Bill 670, “Fully autonomous vehicles; commercial use, civil penalty.” March 3, 2026 House Transportation Committee, ...

On Fri day, Congressman John Garamendi (CA-08), U.S. Senators Elizabeth Warren (D-Mass.), Chris Coons (D-De.), and Ron Wyden (D-Ore.), Ranking ...

More than 90% of drugs that appear safe and effective in animal studies ultimately fail once they reach human trials, and the consequences are staggering: billions of dollars wasted, delays in new ...

LearnWorlds, an AI-first learning management system, today released findings from the first comprehensive study on artificial intelligence adoption in customer education, revealing that while 87% of ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

This article explores the intersection between drinking and nutrition to reveal how alcohol-induced malnutrition can ...

Pew Research Center is a nonpartisan, nonadvocacy fact tank that informs the public about the issues, attitudes and trends shaping the world.

Holding: The Anti-Injunction Act does not bar a challenge to the constitutionality of the Affordable Care Act"s "individual mandate" provision, which requires virtually all Americans to obtain health ...

Global fertility is declining, yet it remains unclear whether and how climate-related hazards contribute to realized fertility change. This paper combines global fertility data with disaster records ...

The Universidad Carlos III de Madrid (UC3M), in collaboration with Neovantas, has presented the results of the 4th edition of the Spanish Innovation ...

AbbVie today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous ...